Hydroxocobalamin for initial and long-term therapy for vitamin B12 deficiency

Area of Science:

• Endocrinology
• Hematology
• Clinical Pharmacology

Background:

• Vitamin B12 deficiency requires effective long-term management.
• Hydroxocobalamin is a common treatment for vitamin B12 deficiency.
• Understanding long-term treatment effects on vitamin B12 levels is crucial.

Purpose of the Study:

• To evaluate the long-term effects of hydroxocobalamin maintenance therapy on serum cobalamin levels.
• To investigate the impact of initial depot treatment intensity on cobalamin levels over time.
• To assess the role of antibodies to transcobalamin II (TC II) in treatment response.

Main Methods:

• Seventeen patients with vitamin B12 deficiency received maintenance therapy with 1 mg hydroxocobalamin intramuscularly every three months.
• Initial treatment involved one or two series of five intramuscular injections on alternate days.
• Serum cobalamins, unsaturated B12 binding capacity (UB12BC), and total B12 binding capacity (TB12BC) were monitored.

Main Results:

• Abnormally high serum cobalamin levels were observed in some patients after 7-12 years, particularly those receiving two initial depot series close together.
• No increase in UB12BC was noted in these cases, unlike patients who developed antibodies to TC II.
• A single depot series followed by monthly maintenance injections maintained normal serum cobalamin, UB12BC, and TB12BC levels.

Conclusions:

• Intensive initial depot treatment with hydroxocobalamin may lead to elevated serum cobalamin levels during long-term maintenance.
• The development of antibodies to TC II is associated with changes in B12 binding capacity.
• A simplified hydroxocobalamin regimen (one depot series plus monthly injections) effectively maintains normal vitamin B12 status.